Form 4: 5AM entities disclose August insider sales in SKYE
Rhea-AI Filing Summary
Skye Bioscience insiders reported multiple sales of common stock on August 21-22, 2025. Entities affiliated with 5AM sold a total of 231,405 shares across two days at weighted-average prices of $3.57 (sales on 08/21) and $3.42 (sales on 08/22), with transaction prices in footnotes ranging from $3.30 to $3.69. After the reported transactions, the filing shows beneficial ownership positions including 1,621,043, 63,963, 1,457,064, 57,493 and a block of 8,167,206 shares held indirectly by 5AM-affiliated entities. The report is signed by the applicable 5AM entities and individual managing members.
Positive
- None.
Negative
- Insider sales of 231,405 shares executed on 08/21-08/22/2025 at weighted-average prices of $3.57 and $3.42 respectively.
- Large remaining indirect holdings disclosed (e.g., 8,167,206 shares by 5AM Ventures VII, L.P.), indicating concentrated ownership despite the sales.
- No reason for the sales provided in the filing; only transaction details and footnotes about price ranges are disclosed.
Insights
TL;DR: Significant insider sales totaling 231,405 shares over two days may be viewed negatively by investors.
The filing documents concentrated dispositions by multiple 5AM-affiliated reporting persons on 08/21/2025 and 08/22/2025, with weighted-average sale prices of $3.57 and $3.42 respectively and per-share price ranges disclosed in footnotes. While the filing provides post-transaction beneficial ownership figures for each reporting entity, it does not state reasons for the sales or indicate any offsetting purchases. For market participants, the transaction size and concentrated timing are material data points to integrate into trading-volume and insider-activity analyses.
TL;DR: The Form 4 appears procedurally complete and discloses indirect holdings via multiple 5AM entities.
The report identifies the reporting persons, their addresses, and the chain of indirect ownership (e.g., 5AM Partners as general partner of listed funds), and includes required explanatory footnotes about weighted-average pricing and relationships. Signatures from relevant managing members and individuals are present. The filing does not contain governance actions, related-party agreements, or any expressed intent beyond the recorded sales, so its governance implications are limited to disclosure of ownership structure and realized dispositions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 163,979 | $3.42 | $561K |
| Sale | Common Stock | 6,470 | $3.42 | $22K |
| Sale | Common Stock | 58,642 | $3.57 | $209K |
| Sale | Common Stock | 2,314 | $3.57 | $8K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
